InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Javitt Jonathan C, Chief Executive Officer. Insider active across 1 company, notably NRX Pharmaceuticals, Inc.. Aggregated, 18 filings have been recorded. Split: 5 buys · 6 sells. Total volume traded: €7.2m. History available since 1 June 2022. The latest transaction was filed on 17 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
40,000 shares@ US$1.170.7% of flowCommon StockSEC:0001415889-24-029694:0
Ideal exit: 13 Sept 2025 (T+270)
100,000 shares@ US$0.330.5% of flowCommon StockSEC:0001104659-23-094815:0
Ideal exit: 19 May 2024 (T+270)
200,000 shares@ US$0.3221.0% of flowCommon StockSEC:0001104659-23-094406:0
Ideal exit: 18 May 2024 (T+270)
400,000 shares@ US$1.006.4% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-22-012324:0
13,730 shares@ US$1.50411.8% of flowcommon stockSEC:0000880984-22-000017:0
133,719 shares@ US$1.0211.6% of flowcommon stockSEC:0000880984-22-000015:0
49,200 shares@ US$1.00634.3% of flowcommon stockSEC:0000880984-22-000014:0
784,063 shares@ US$1.009468.4% of flowCommon StockSEC:0000880984-22-000009:0
2,000,000 shares0Common StockSEC:0000880984-22-000008:0
243,596 shares@ US$0.7024100.0% of flowCommon StockSEC:0000880984-22-000007:0
100,000 shares@ US$0.581.0% of flowCommon StockSEC:0000921895-22-001874:0
Ideal exit: 26 Feb 2023 (T+270)
100,000 shares@ US$58.0099.0% of flowCommon StockSEC:0000921895-22-001872:0
Ideal exit: 26 Feb 2023 (T+270)
434,594 sharesCommon StockSEC:0000950142-21-003505:0
434,594 sharesCommon StockSEC:0000950142-21-003505
13,971,864 sharesCommon StockSEC:0000950142-21-001944:0
13,971,864 sharesCommon StockSEC:0000950142-21-001944
46,332 sharesCommon StockSEC:0000950142-21-001945:0
46,332 sharesCommon StockSEC:0000950142-21-001945
18 of 18 declarations
About Javitt Jonathan C
Jonathan C. Javitt is the Chief Executive Officer and Chief Scientist of NRX Pharmaceuticals, Inc. In this role, he oversees the company's operations and research initiatives. His expertise in life sciences is essential for guiding the development of new therapies. As CEO, he plays a key role in the overall strategy and direction of the company.
